| Followers | 144 |
| Posts | 28017 |
| Boards Moderated | 4 |
| Alias Born | 02/07/2004 |
Tuesday, December 29, 2020 9:00:33 AM
ARK is buying RDHL and PSTI
This by itself does not impress me too much:
-Ark has many (relative)small investments in
many stocks, very wise strategy for spreading
their risk/reward portfolio.
-Tutes (in general) buying into a company is
indeed a sign of confidence for us retail
investors due to their ability to perform
better DD, however they are not above failure.
OTOH, same as their buying in, tutes may, due
to various reasons, sell off, causing a crash
in share price regardless of the specific stock
in questions achievements (or lack therof).
My personal opinion (as i stated before) is that
RDHL has much better chances of success than
PSTI.
Having said that, i of course wish you good
fortune in both RDHL and PSTI!
Recent RDHL News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/07/2026 09:00:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2026 04:15:13 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/04/2026 08:40:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/30/2026 11:02:46 AM
- RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease • PR Newswire (US) • 04/30/2026 11:00:00 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/27/2026 12:18:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/27/2026 12:04:19 PM
- RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights • PR Newswire (US) • 04/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 10:09:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/22/2026 12:02:19 PM
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 • PR Newswire (US) • 04/22/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/14/2026 11:00:07 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 02:00:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 12:01:02 PM
- Joint U.S. Commercialization of RedHill's Talicia® Commences • PR Newswire (US) • 02/25/2026 12:00:00 PM
